{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-021410","form_type":"8-K","ticker":"CING","cik":"0001862150","company_name":"Cingulate Inc.","filed_at":"2025-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.863946+00:00","generated_at":"2026-05-16T22:37:41.090521+00:00","sec_items":["1.01","2.03","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Cingulate completes $6M debt financing, appoints Bryan Downey as CCO","bullets":["Issued $6.57M unsecured promissory note at 9% interest, maturing 18 months, to Avondale Capital for $6M net proceeds.","Bryan Downey appointed Chief Commercial Officer; granted 30,000 options at $3.80/share, vesting over 4 years.","Cash runway extended into Q2 2026; proceeds for working capital and general corporate purposes.","FDA accepted NDA for CTx-1301 (ADHD); PDUFA target action date May 31, 2026.","Note includes monthly redemption up to $660k after PDUFA; company can defer up to 2 redemptions with 1% fee."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-021410","json":"https://secwatch.observer/filing/0001493152-25-021410.json","markdown":"https://secwatch.observer/filing/0001493152-25-021410.md","text":"https://secwatch.observer/filing/0001493152-25-021410.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1862150/000149315225021410/0001493152-25-021410-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1862150/000149315225021410/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T22:37:41.090521+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"17b578cc67e8e458aedad9911e34c4f4d64d9c2e","claim":"Cingulate Inc. incurred loan of $6,570,000 with Avondale Capital, LLC at 9% per annum maturing 18 months after its issuance date.","evidence_excerpt":"On November 7, 2025, Cingulate, Inc. (the “Company”), entered into a Note Purchase Agreement (the “Note Purchase Agreement”) with Avondale Capital, LLC, a Utah limited liability company (“Lender”), pursuant to which the Company issued and sold to Lender an unsecured promissory note (the “Note”) in the amount of $6,570,000 (the “Principal Amount”).","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1862150/000149315225021410/0001493152-25-021410-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"loan"},{"label":"Principal","value":"$6,570,000"},{"label":"Counterparty","value":"Avondale Capital, LLC"},{"label":"Rate","value":"9% per annum"},{"label":"Maturity","value":"18 months after its issuance date"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}